Neuroendocrine tumours trials in Spain

In Spain 16 Also abroad 243

16 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 2Taking people
Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)
Where
Barcelona, Madrid, Oviedo
Age
12 years and over
People
355 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to joinNCT04924075 · EU 2023-504853-11-00
Phase 2/3Taking people
Zanzalintinib Versus Everolimus in Participants With Locally Advanced or Metastatic Neuroendocrine Tumors
Where
Barcelona, Madrid, Murcia, Oviedo, Santander, Santiago de Compostela, Seville, Valencia, Zaragoza
Age
18 years and over
People
440 worldwide
Run by
Exelixis
See details and how to joinNCT06943755 · EU 2025-521043-20-00
No phaseTaking people
Multicenter Study for External Validation of the TB-NET Score
Where
Madrid, Santander
Age
18 years and over
People
400 worldwide
Run by
Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz
See details and how to joinNCT07903532
Phase 3Taking people
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
Where
Badalona, Barcelona, Madrid, Málaga, Pamplona, Santander, Sevilla, Valencia
Age
18 years and over
People
390 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07544654 · EU 2025-523869-22-00
Phase 1/2Not yet taking people in Spain
DAREON®-36: A Study to Test Obrixtamig in Combination With ZL-1310 in People With Advanced Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
L'Hospitalet de Llobregat, Madrid, Valencia
Age
18 years and over
People
60 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT07707895 · EU 2026-525634-27-00
Phase 3Taking people
A clinical trial of belzutifan and other treatments in people with solid tumors or von Hippel-Lindau (VHL)-related tumors (MK-6482-043)
Where
Barcelona, Madrid
Age
18 years and over
People
134 worldwide
Run by
Merck Sharp & Dohme LLC
See details and how to join2025-524160-38-00 · EU 2025-524160-38-00
Phase 1Taking people
Phase I Study of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Where
Barcelona, Madrid
Age
18 years to 100 years
People
116 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT07006727 · EU 2024-519111-34-00
Phase 3Taking people
Randomized Interval Assessment Trial of Lu177-Dotatate in Slowly Progressive G1-2 Advanced Midgut Neuroendocrine Tumors
Where
Barcelona, Burgos, Granada, L'Hospitalet de Llobregat, Madrid, Oviedo, Seville, Valencia
Age
18 years and over
People
166 worldwide
Run by
Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT06878664 · EU 2024-517921-14-00
Phase 3Taking people
Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Oviedo, Salamanca
Age
12 years to 100 years
People
240 worldwide
Run by
Novartis Pharmaceuticals
See details and how to joinNCT06784752 · EU 2024-518325-15-00
Phase 3Taking people
Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide versus Durvalumab, Carboplatin, and Etoposide in First-Line ES-SCLC (DeLLphi-312)
Where
Barcelona, Madrid, Majadahonda, Málaga, Valencia
Age
18 years and over
People
156 worldwide
Run by
Amgen Inc.
See details and how to join2024-520050-38-00 · EU 2024-520050-38-00
Phase 2Taking people
DAREON™-5: A Study to Test Whether Different Doses of BI 764532 Help People With Small Cell Lung Cancer or Other Neuroendocrine Cancers
Where
Barcelona, Madrid, Málaga, Valencia
Age
18 years and over
People
204 worldwide
Run by
Boehringer Ingelheim
See details and how to joinNCT05882058 · EU 2023-504247-13-00
Phase 1/2Taking people
A Study of IDE849 in Patients With DLL3 Expressing Tumors Including Small Cell Lung Cancer
Where
Madrid, Pozuelo de Alarcón, Sevilla
Age
18 years and over
People
262 worldwide
Run by
IDEAYA Biosciences
See details and how to joinNCT07174583 · EU 2025-523438-24-00
Phase 1/2Taking people
Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).
Where
Boadilla del Monte
Age
3 years and over
People
25
Run by
Fundación de investigación HM
See details and how to joinNCT06607692 · EU 2024-512613-40-00
Phase 3Taking people
Efficacy and Safety of Radiotherapy Compared to Everolimus in Somatostatin Receptor Positive Neuroendocrine Tumors of the Lung and Thymus.
Where
Barcelona, L'Hospitalet de Llobregat, Madrid, Oviedo, Santiago de Compostela, Seville, Valencia
Age
18 years and over
People
170 worldwide
Run by
Grupo Espanol de Tumores Neuroendocrinos
See details and how to joinNCT05918302 · EU 2022-502154-13-00
No phaseTaking people
Prophylactic Cholecystectomy in Midgut NETs Patients Who Require Primary Tumor Surgery.
Where
Badalona, Barcelona, L'Hospitalet de Llobregat, Madrid
Age
18 years and over
People
100
Run by
Hospital Universitari de Bellvitge
See details and how to joinNCT04735198
No phaseTaking people
Spanish Series of Patients Treated With the Radionuclide Lutetium177
Where
Barcelona, Burgos, Ciudad Real, El Palmar, Getafe, Granada, L'Hospitalet de Llobregat, Madrid, Majadahonda, Oviedo, Palma de Mallorca, Pamplona, Santiago de Compostela, Valencia
Age
18 years to 100 years
People
5,000
Run by
Sociedad Española de Medicina Nuclear e Imagen Molecular
See details and how to joinNCT04949282